18F-fluorothymidine kinetics of malignant brain tumors

Schiepers, Christiaan; Chen, Wei; Dahlbom, Magnus; Cloughesy, Timothy F.; Hoh, Carl K.; Huang, Sung‐Cheng

doi:10.1007/s00259-006-0354-5

Cited by 72 publications

(85 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Partial-volume correction was applied by using a recovery coefficient of 0.6 for the blood curve. This choice was based on the iliac artery size of 4-7 mm and on recovery coefficients determined for our PET system based on earlier work (2,39). For the output function we used a recovery coefficient of 1 because the tumors were, on average, .10 mL.…”

Section: Discussionmentioning

confidence: 99%

1-¹¹C-Acetate Kinetics of Prostate Cancer

Schiepers¹,

Hoh²,

Nuyts³

et al. 2008

J Nucl Med

Self Cite

View full text Add to dashboard Cite

18 F-FDG is in widespread use in cancer imaging but has limited utility in staging and monitoring of prostate cancer. 1-11 CLabeled acetate, a substrate for the citric acid cycle, is superior. The kinetics of prostate tumors were investigated. Methods: Ten patients with primary prostate cancer, 10 with recurrent tumor, and 2 men with benign prostate hypertrophy were studied. After administration of 5.5 MBq/kg 1-11 C-acetate, dynamic PET of the pelvis was acquired for 20 min. Images were reconstructed with iterative algorithms, and corrections for attenuation and scatter were applied. Factor analysis produced factor images, representing iliac vessels and the prostate from which blood-input and tissue-output functions were derived with simple thresholding techniques. Five different kinetic models were applied to the dynamic data to estimate the rate constants. Results: The standard 3-compartment, 2-tissue model was able to describe 1-11 C-acetate kinetics of the prostate. The model could be reduced to 3 parameters by setting the tissue blood fraction and release from the second tissue compartment (k 4 ) to zero. Correction for metabolites appeared to be necessary. This reduced model performed marginally better than a 2-compartment model. A significant correlation was found between the influx rate constant (K) and acetate uptake (standardized uptake value) for primary tumors (r 5 0.91), whereas there was no correlation for recurrent tumors (r 5 20.17). Patlak graphical analysis provided accurate parameter estimates. Conclusion: A 3-compartment, 3-parameter model is able to describe adequately the acetate kinetics in prostate cancer. Significant differences between primary and recurrent cancer were found for transport k 1 , influx K, distribution volume V d , as well as early (6-10 min) and late (15-20 min) 1-11 C-acetate uptake.

show abstract

Section: Discussionmentioning

confidence: 99%

1-¹¹C-Acetate Kinetics of Prostate Cancer

Schiepers¹,

Hoh²,

Nuyts³

et al. 2008

J Nucl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chen et al used their IDIF method for [ 18 F]-FDG (Chen et al, 1998) to measure cerebral metabolic rate for glucose in young adults at genetic risk for late-onset Alzheimer's dementia (Reiman et al, 2004), to differentiate healthy subjects from Alzheimer's patients (Chen et al, 2006), and to evaluate healthy adults reporting dream-enactment behaviors (Caselli et al, 2006). Schiepers et al used an IDIF method based on factor analysis to study patients with brain tumors using [ 18 F]-fluorothymidine (Schiepers et al, 2007b) and [ 18 F]-FDOPA (Fueger et al, 2010;Schiepers et al, 2007a). Although this method was never validated for brain studies against a reference input function, especially vis-à-vis the recovery coefficient used for partial volume correction, Schiepers et al had previously shown that it yielded reliable input functions for bone disorders with [ 18 F]-fluoride (Schiepers et al, 1997), in breast cancer with [ 18 F]-FDG (Schiepers et al, 1998), in prostate cancer with [ 11 C]-acetate (Schiepers et al, 2000(Schiepers et al, , 2002b(Schiepers et al, , 2008 (Schiepers et al, 2002a;Wu et al, 1995).…”

Section: How Often Is Image-derived Input Function Used In Positron Ementioning

confidence: 99%

“…Schiepers et al (2007b) used a fixed recovery coefficient to scale factor analysis based input functions from transverse sinuses. However, the accuracy of this scaling was not tested against the gold standard of arterial input function.…”

Section: Can Blood Sampling Really Be Avoided?mentioning

confidence: 99%

Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities

Zanotti‐Fregonara

Chen

Liow

et al. 2011

J Cereb Blood Flow Metab

198

203

View full text Add to dashboard Cite

Quantitative positron emission tomography (PET) brain studies often require that the input function be measured, typically via arterial cannulation. Image-derived input function (IDIF) is an elegant and attractive noninvasive alternative to arterial sampling. However, IDIF is also a very challenging technique associated with several problems that must be overcome before it can be successfully implemented in clinical practice. As a result, IDIF is rarely used as a tool to reduce invasiveness in patients. The aim of the present review was to identify the methodological problems that hinder widespread use of IDIF in PET brain studies. We conclude that IDIF can be successfully implemented only with a minority of PET tracers. Even in those cases, it only rarely translates into a less-invasive procedure for the patient. Finally, we discuss some possible alternative methods for obtaining less-invasive input function.

show abstract

“…the role of novel amino acid tracers was discussed in different studies O-(2-18 F-fluoroetyl)-L -tyrosine ( 18 F-FET), 3,4-dixydroxy-6-18 F-fluoro-L -phenylanine ( 18 F-FDOPA). [25,26,27] In conclusion, EBRT in combination with chemotherapy (Temozolomide) is the treatment of choice for patients with high grade glioma after surgery. Recommended total dose is 60.0Gy with 1.8 or 2.0 Gy per fraction.…”

Section: Discussionmentioning

confidence: 99%

Post-therapeutical changes in the brain: novel trends in imaging and their infuence on external beam radiotherapy

Chorváth¹,

Bolješíková²,

Pruzincová³

et al. 2009

neo

View full text Add to dashboard Cite

Presented is the analysis of patients who underwent external beam radiotherapy (EBRT) to the brain in the period from 2003 to 2006 at the department of Radiation Oncology of the St. Elisabeth Cancer Institute.The aim of our analysis was to identify risk factors of late delayed therapy induced injuries (LDTI) in the brain. The patients were regularly examined with magnetic resonance (MRI), including conventional and advanced techniques: perfusion imaging (pMRI), diffusion weighted imaging (DWI), MRI spectroscopy (MRS). The results from MRI were correlated with 18 fluoro-deoxyglucose positron emission tomography ( 18 FDG/PET) scans, as none of the listed method is sufficiently sensitive and specific by itself. Also clinical data records and treatment plans of these patients were analyzed.In our cohort we found 6 patients with abnormal post-therapeutical changes, 4 of them with MR and 18 FDG/PET scans characteristics for LDTI -radiation necrosis. In one patient biopsy was performed and radiation necrosis (RN) was confirmed.

show abstract

18F-fluorothymidine kinetics of malignant brain tumors

Cited by 72 publications

References 15 publications

1-¹¹C-Acetate Kinetics of Prostate Cancer

1-¹¹C-Acetate Kinetics of Prostate Cancer

Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities

Post-therapeutical changes in the brain: novel trends in imaging and their infuence on external beam radiotherapy

Contact Info

Product

Resources

About

18F-fluorothymidine kinetics of malignant brain tumors

Cited by 72 publications

References 15 publications

1-11C-Acetate Kinetics of Prostate Cancer

1-11C-Acetate Kinetics of Prostate Cancer

Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities

Post-therapeutical changes in the brain: novel trends in imaging and their infuence on external beam radiotherapy

Contact Info

Product

Resources

About

1-¹¹C-Acetate Kinetics of Prostate Cancer

1-¹¹C-Acetate Kinetics of Prostate Cancer